文献速递胸部技术与安全PETCT

基于[18F]-FDG PET/CT的影像基因组学模型预测非小细胞肺癌驱动基因突变

Predictive [18F]-FDG PET/CT-Based Radiogenomics Modelling of Driver Gene Mutations in Non-small Cell Lung Cancer.
PubMed 文献 · Acad Radiol · 2024-07-14

本研究为IRB批准的回顾性研究,纳入128例接受术前[18F]-FDG PET/CT并做基因组分析的手术治疗非小细胞肺癌患者,提取PET/CT影像组学特征构建模型预测驱动基因突变。53%样本携带≥3个基因突变,TP53突变占55%、KRAS改变占26%、EGFR改变占17%;联合PET/CT特征预测TP53的约登指数最高为0.70,仅PET特征预测KRAS为0.57,仅CT特征预测EGFR为0.60,显示中等至良好预测能力。

要点

  • 联合PET/CT影像组学特征预测TP53突变约登指数最高(0.70)。
  • 仅PET特征预测KRAS突变约登指数0.57,仅CT特征预测EGFR突变约登指数0.60。
  • 53%的肿瘤样本携带三个或以上基因突变。

核心结论

  • 影像组学特征与NSCLC驱动基因突变存在中等至良好相关性,联合[18F]-FDG PET/CT影像组学特征可提高基因组谱的预测能力。

研究设计与样本

  • IRB批准的回顾性研究,纳入2004年12月至2014年1月在本机构接受手术治疗并做原发肿瘤基因组分析的NSCLC患者203例,其中128例(平均年龄62.4±10.8岁,范围35-84岁)术前接受[18F]-FDG PET/CT初始分期而纳入;PET和CT图像分割与特征提取使用开源软件平台LIFEx(Version 6.30,lifexsoft.org)半自动完成;分子谱来自基于网络的资源cBioPortal.ca for Cancer genomics的不同NGS panel;构建两种统计模型评估影像组学特征对驱动基因突变的预测能力。

诊断标准与关键数值

  • TP53突变预测:联合PET/CT特征约登指数最高为0.70。
  • KRAS突变预测:仅PET特征约登指数最高为0.57。
  • EGFR突变预测:仅CT特征约登指数最高为0.60。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

RATIONALE AND OBJECTIVES: To investigate whether [18F]-FDG PET/CT-derived radiomics may correlate with driver gene mutations in non-small cell lung cancer (NSCLC) patients.

MATERIALS AND METHODS: In this IRB-approved retrospective study, 203 patients with surgically treated NSCLC who underwent subsequent genomic analysis of the primary tumour at our institution between December 2004 and January 2014 were identified. Of those, 128 patients (mean age 62.4 ± 10.8 years; range: 35-84) received preoperative [18F]-FDG PET/CT as part of their initial staging and thus were included in the study. PET and CT image segmentation and feature extraction were performed semi-automatically with an open-source software platform (LIFEx, Version 6.30, lifexsoft.org). Molecular profiles using different next-generation sequencing (NGS) panels were collected from a web-based resource (cBioPortal.ca for Cancer genomics). Two statistical models were then built to evaluate the predictive ability of [18F]-FDG PET/CT-derived radiomics features for driver gene mutations in NSCLC.

RESULTS: More than half (68/128, 53%) of all tumour samples harboured three or more gene mutations. Overall, 55% of tumour samples demonstrated a mutation in TP53, 26% of samples had alterations in KRAS and 17% in EGFR. Extensive statistical analysis resulted in moderate to good predictive ability. The highest Youden Index for TP53 was achieved using combined PET/CT features (0.70), for KRAS using PET features only (0.57) and for EGFR using CT features only (0.60).

CONCLUSION: Our study demonstrated a moderate to good correlation between radiomics features and driver gene mutations in NSCLC, indicating increased predictive ability of genomic profiles using combined [18F]-FDG PET/CT-derived radiomics features.

来源:Acad Radiol,查看原文。版权归原作者所有。

引用

  1. Hinzpeter R, Kulanthaivelu R, Kohan A, et al. Predictive [18F]-FDG PET/CT-Based Radiogenomics Modelling of Driver Gene Mutations in Non-small Cell Lung Cancer. Acad Radiol. 2024. PMID: 38997880. doi:10.1016/j.acra.2024.06.038

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。